Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HK1 | P19367 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GALK1 | P51570 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345703 | 0.83 | MAPT (0.47) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL407439 | 0.79 | NPC1 (0.70) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL688577 | 0.79 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2090031 | 0.76 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9210837 | 0.76 | MEN1 (0.38) | NPC1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL34907 | 0.75 | — | — | |
| SCHEMBL689201 | 0.72 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4078314 | 0.72 | MEN1 (0.35) | MAPTMEN1KMT2AGAAHTR5A | |
| SCHEMBL615272 | 0.72 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL338538 | 0.71 | CES1 (0.45) | NPC1KDM4EALDH1A1RAB9AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11965102-B2 | Photochromic annelated naphthopyrane systems with special substituents, for attaining rapid lightening speeds | RODENSTOCK GMBH (DE) | 2024-04-23 | — | — | US | claimed |
| EP-4240797-A1 | COMBINATION OF SPECIFIC ANNELLATED NAPHTHOPYRANE ISOMERS | Rodenstock GmbH (DE) | 2023-09-13 | — | — | EP | claimed |
| WO-2023135127-A1 | COMBINATION OF SPECIFIC ANNELLATED NAPHTHOPYRANE ISOMERS | RODENSTOCK GMBH (DE) | 2023-07-20 | — | — | WO | claimed |
| EP-3807258-B1 | PHOTOCHROMIC ANNELATED NAPHTHOPYRANE SYSTEMS WITH SPECIAL SUBSTITUENTS, FOR ATTAINING RAPID LIGHTENING SPEEDS | RODENSTOCK GMBH (DE) | 2021-10-20 | — | — | EP | claimed |
| US-20210253865-A1 | PHOTOCHROMIC ANNELATED NAPHTHOPYRANE SYSTEMS WITH SPECIAL SUBSTITUENTS, FOR ATTAINING RAPID LIGHTENING SPEEDS | RODENSTOCK GMBH (DE) | 2021-08-19 | — | — | US | claimed |
| EP-3515991-B1 | PHOTOCHROMIC MULTIPLE RING-FUSED NAPHTHOPYRANS HAVING EXTREME LONGWAVE ABSORPTION EXTENDING FAR INTO THE VISIBLE WAVELENGTH RANGE | RODENSTOCK GMBH (DE) | 2020-10-07 | — | — | EP | claimed |
| US-10647852-B2 | Photochromic multiple ring-fused naphthopyrans having extreme longwave absorption extending far into the visible wavelength range | RODENSTOCK GMBH (DE) | 2020-05-12 | — | — | US | claimed |
| US-20190284397-A1 | PHOTOCHROMIC MULTIPLE RING-FUSED NAPHTHOPYRANS HAVING EXTREME LONGWAVE ABSORPTION EXTENDING FAR INTO THE VISIBLE WAVELENGTH RANGE | RODENSTOCK GMBH (DE) | 2019-09-19 | — | — | US | claimed |
| EP-3515991-A1 | PHOTOCHROMIC MULTIPLE RING-FUSED NAPHTHOPYRANS HAVING EXTREME LONGWAVE ABSORPTION EXTENDING FAR INTO THE VISIBLE WAVELENGTH RANGE | Rodenstock GmbH (DE) | 2019-07-31 | — | — | EP | claimed |
| US-10077274-B2 | UV-curing-compatible photochromic fused naphthopyrans | RODENSTOCK GMBH (DE) | 2018-09-18 | — | — | US | claimed |
| US-20080262248-A1 | Photochromic Spirodihydrophenanthropyrans | RODENSTOCK GMBH (DE) | 2008-10-23 | — | — | US | claimed |
| EP-1945625-A1 | PHOTOCHROMIC SPIRODIHYDROPHENANTHROPYRANS | Rodenstock GmbH (DE) | 2008-07-23 | — | — | EP | claimed |
| WO-2007054240-A1 | PHOTOCHROMIC SPIRODIHYDROPHENANTHROPYRANS | RODENSTOCK GMBH (DE) | 2007-05-18 | — | — | WO | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| EP-1301187-B1 | PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) | NOVO NORDISK AS (DK) | 2005-07-06 | — | — | EP | claimed |
| EP-0519353-B1 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-08-16 | — | — | EP | claimed |
| US-6043247-A | A SUBSTITUTED ACRYLIC ACIDS FOR USE IN TREATMENT OF HUMAN AND ANIMAL DISORDERS, AND PURIFICATION OF PROTEINS OR GLYCOPROTEINS, AND TO THEIR USE IN DIAGNOSIS | NOVO NORDISK A/S (DK) | 2000-03-28 | — | — | US | claimed |
| EP-0458207-B1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-03-26 | — | — | EP | claimed |
| EP-0519353-A2 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-23 | — | — | EP | claimed |
| EP-0458207-A2 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077274-B2 | UV-curing-compatible photochromic fused naphthopyrans | GNE, ALDH1A2, NQO1 | NPC1 3206/4885MAPK13 4034/4885MAPK12 4154/4885 |
| US-10647852-B2 | Photochromic multiple ring-fused naphthopyrans having extreme longwave absorption extending far into the visible wavelength range | IGLV6-57, PUF60, STRA6 | NPC1 1002/4885MAPK13 1684/4885MAPK12 2097/4885 |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | BACE1, BACE2, APH1B | NPC1 781/4885MAPK13 4385/4885MAPK12 3637/4885 |
| US-20080262248-A1 | Photochromic Spirodihydrophenanthropyrans | ALDH1A2, QDPR, RB1 | NPC1 3631/4885MAPK13 2931/4885MAPK12 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.